$BIIB Biogen Idec Inc. is something to pay close a
Post# of 122
" Analyst Geoff Meacham mentioned that while Biogen is expected to report POC data from several high impact studies in 1H16, investors should first evaluate the health of the company’s MS franchise and the overall growth profile.
The analyst expects the company to report in-line or better-than-expected revenue growth and non-GAAP EPS for FY16. Consensus expectations of the company recording WW Tecfidera growth of over 10 percent in 2016 look achievable, given the 4-5 percent and more increases expected across the MS portfolio."
Read more: http://www.benzinga.com/analyst-ratings/analy...z3xzAGGzUF